Citations

Clear

13603 citation(s) found for "_, _".

Reduction in respiratory muscle strength following a series of preparatory and maximal static, dry breath-holds
Hubbard, Colin D. , Vrdoljak, Dario , Cross, Troy J. , Lovering, Andrew T. , Drviš, Ivan, Dujić, Željko , Foretić, Nikola , Duke, Joseph W. , Coombs, Geoff B , Cross, Troy James , Taylor, Bryan J , Lovering, Andrew T , Dujić, Željko , Foretić, Nikola , Duke, Joseph W , Hubbard, Colin D. , Taylor, Bryan J.

Mayo Clinic

Journal of Applied Physiology | October 3, 2025 | Volume: 139 | Issue: 5 | Pages: 1235-1245

10.1152/japplphysiol.00256.2025 | PMID 41042814 Get It

Respiratory muscle fatigue could occur following involuntary breathing movements during maximal breath-holds. We measured respiratory muscle strength pre and post three preparatory and maximal breath-holds. We found significant reductions in diaphragm strength and total inspiratory and expiratory strength in some, but not all, divers. Divers that had respiratory muscle fatigue had a lower pseudo O 2 delivery (HR × [Formula: see text]) during the struggle phase. This suggests that reduced oxygen delivery may contribute to respiratory muscle fatigue during a breath-hold.
P14.19.B PRIMARY HISTIOCYTIC SARCOMA OF THE CENTRAL NERVOUS SYSTEM: REPORT OF TWO CASES, INCLUDING A CASE WITH PROMINENT INTRAVENTRICULAR DISSEMINATION
Donev, Kliment

Mayo Clinic

Neuro-Oncology | October 3, 2025 | Volume: 27 | Issue: Supplement_3 | Pages: iii143-iii143

10.1093/neuonc/noaf193.480 Get It

Abstract BACKGROUND Primary Central Nervous System histiocytic sarcoma is rare aggressive malignant neoplasm with less that 50 cases reported in the literature. They usually harbor variable genetic alteration including MAPK and PI3K pathways as well as tumor suppressor genes TP53 and CDKN2A/B, among others. Herein, two additional two cases of Primary CNS histiocytic sarcoma are reported. MATERIAL AND METHODS N/A. RESULTS Case 1: 78-year-old man with past medical history significant for renal cell carcinoma (25 years ago), and chronic kidney disease, presented with gait instability and multiple falls. Magnetic resonance imaging (MRI) and Positron Emission Tomography-Computed Tomography (PET/CT) scan revealed prominent intraventricular dissemination with multiple enhancing masses along the ventricular system and periventricular areas that were enlarging over time. In addition, there were multiple intramedullary, central canal and pial surface lesions in the cervical spine. Also left adreanal adenoma was seen and small indeterminate lesions in the liver and left kidney. Overall findings were suspicious for primary CNS malignancy. Biopsy revealed histiocytic sarcoma. Given the advanced stage of disease the patient opted for palliative therapy and eventually passed away 14 days after the diagnosis. Case 2: 56-year-old woman with medical history of breast carcinoma (2021) and hypertension presented with one year history of bilateral feet and calf paresthesia, followed by repeated falls and eventually becoming wheelchair-bound. She also developed hearing impairment, dysarthria, dysphagia and abnormal extraocular movements. Multiple brain MRIs revealed extensive extra-axial and leptomeningeal enhancement involving bilateral cavernous sinuses, optic chiasm and tracts, prepontine cistern and adjacent temporal regions. Nodular enhancement along cranial nerves and brainstem was also noted. Excisional biopsy revealed histiocytic sarcoma. Patient clinically deteriorated rapidly and passed away 10 days after the diagnosis. Pathology: Both cases revealed high-grade malignancy composed of sheets of large cells with ample cytoplasm. Significant nuclear pleomorphism and multinucleation was seen. Background chronic inflammation was present. Large neoplastic cell were positive for histiocytic markers, including CD68, CD163, CD4, PU.1 and S100, while all other lymphoma, epithelial, melanocytic and sarcoma markers were negative. MayoComplete Histiocytic Neoplasm panel was negative for all 8 mutations tested. CONCLUSION Primary CNS histiocytic sarcoma is a very rare entity. These two cases support the previously reported aggressive clinical course of primary CNS histiocytic sarcoma. Histiocytic sarcoma can involved any area of central nervous system, but prominent intraventricular dissemination as seen in case 1 has been previously reported in only case.
OS04.4.A RENEU LONG-TERM FOLLOW-UP (LTFU) UPDATE: A PIVOTAL, PHASE 2B TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED SYMPTOMATIC PLEXIFORM NEUROFIBROMA (PN)
Babovic‐Vuksanovic, Dusica , Shuhaiber, Hans, Viskochil, David , Weintraub, Lauren , Langseth, Abraham, Lokku, A, Hajjar, Fouad, Antony, Raju, Schiff, David , Nevel, Kathryn , Moertel, Christopher L. , Sidhu, Alpa , Meade, Julia , Hirbe, Angela C. , Weber, Michael , Lokku, Armend, Antony, R, Raslan, Ahmed M , Gershon, Timothy R.

Mayo Clinic

Neuro-Oncology | October 3, 2025 | Volume: 27 | Issue: Supplement_3 | Pages: iii14-iii15

10.1093/neuonc/noaf193.043 Get It

Abstract BACKGROUND Mirdametinib is the first FDA-approved MEK1/2 inhibitor for both adults and children (≥2 years) with NF1 who have symptomatic PN not amenable to complete resection. We report updated results from the LTFU phase of the pivotal, phase 2b ReNeu trial (NCT03962543) evaluating the efficacy and safety of mirdametinib. MATERIALS AND METHODS In ReNeu, mirdametinib capsules or tablets for oral suspension (2 mg/m2 BID, max 4 mg BID) are administered in 3-weeks-on/1-week-off 28-day cycles. Following the 24-cycle (~2 years) treatment phase, patients could continue mirdametinib in an optional LTFU phase. These analyses are inclusive of the treatment and LTFU phases (data cutoff: June 12, 2024; an additional 9 months of cumulative data following the primary analysis). Exploratory analyses reported here included confirmed objective response rate (ORR; proportion of patients with ≥20% reduction of target PN volume from baseline on consecutive MRI scans within 2 to 6 months, assessed by blinded independent central review), duration of response (DoR), change from baseline in target PN volume, and safety. RESULTS Fifty-eight adults and 56 children were dosed with mirdametinib. Median (range) duration of mirdametinib treatment was 21.8 (0.4, 54.4) months in adults and 25.4 (1.6, 48.5) months in children. Among LTFU-eligible patients, 26/31 (84%) adults and 32/37 (86%) children entered the LTFU. Confirmed ORR was 47% (27/58; 95% CI, 33%, 60%) in adults and 55% (31/56; 95% CI, 42%, 69%) in children. Of patients with a confirmed objective response, 18 adults and 19 children achieved a deep response (best target PN volume reduction from baseline of >50%). Median (range) best percentage change from baseline in target PN volume was -41% (-90%, 13%) in adults and -43% (-98%, 48%) in children. Median DoR was not reached. Treatment-related adverse events (TRAEs) in ≥25% of patients were dermatitis acneiform, diarrhoea, nausea, and vomiting in adults, and diarrhoea, dermatitis acneiform, and paronychia in children. Grade ≥3 TRAEs occurred in 17% of adults and 25% of children. Dose interruptions, dose reductions, and discontinuations due to TRAEs occurred in 9%, 17%, and 22%, respectively, of adults, and in 14%, 14%, and 9%, respectively, of children. CONCLUSIONS An increase in confirmed ORR was observed with longer duration of mirdametinib treatment, with additional deep responses achieved in both adults and children with NF1-PN. Mirdametinib continued to be well tolerated with a manageable safety profile and no new safety signals identified in the LTFU phase. SUPPORTED BY SpringWorks Therapeutics, Inc.
P12.53.B DEVELOPMENT AND VALIDATION OF A PRACTICAL PROGNOSTIC MODEL FOR GLIOBLASTOMA INTEGRATING ICAM1 EXPRESSION, RADIOLOGIC FEATURES, AND CLINICAL DATA
Gandhi, Sangeetha, Singh, Olivia , Molina, D, Velásquez, C, García, Virginia, Zadeh, Gelareh, Ocaña-Tienda, Beatriz , Molina, David , Velásquez, C, Mansouri, Alireza , Garcia, V Perez, Mansouri, Sheila

Mayo Clinic

Neuro-Oncology | October 3, 2025 | Volume: 27 | Issue: Supplement_3 | Pages: iii129-iii129

10.1093/neuonc/noaf193.432 Get It

Abstract BACKGROUND Glioblastoma (GBM) is a highly aggressive brain tumour with limited prognostic tools that are broadly implementable in routine clinical settings. Current models often depend on molecular platforms not universally accessible. We aimed to develop and validate a clinically practical prognostic model for GBM that integrates ICAM1 protein expression, imaging-derived tumor morphometrics, and clinical features. MATERIAL AND METHODS We analyzed ICAM1 expression in GBM at the DNA methylation, RNA, and protein levels using public datasets and institutional cohorts, confirming its association with tumor grade and poor survival. ICAM1 protein levels were then quantified via digital pathology in a multi-institutional cohort of 197 newly diagnosed, treatment-naïve GBM patients. Tumor surface irregularity (SIR) was calculated from pre-operative contrast-enhanced MRI using open-source imaging tools. Age at diagnosis was also recorded. These three variables—ICAM1 expression, SIR, and age—were integrated into a Clinical-Imaging-Molecular (CIM) model using multivariable Cox regression. The model was validated in an independent external GBM cohort (n = 20). Survival prediction was assessed using Kaplan-Meier curves, ROC analysis, and concordance index (c-index). RESULTS ICAM1 expression was associated with DNA hypomethylation and significantly correlated with reduced survival at transcriptomic and proteomic levels. Pathway analysis identified associations with immune activation and angiogenesis. In the clinical cohort, high ICAM1 expression, elevated tumor SIR, and older age independently predicted worse survival. The CIM model combining these factors stratified patients into distinct prognostic groups, achieving strong performance (c-index = 0.779, AUC = 0.778). External validation confirmed the model’s predictive utility (median survival difference: 9.1 months, P = 0.009). CONCLUSION We present a validated and clinically applicable prognostic model for GBM that integrates ICAM1 expression, imaging features, and age. The CIM model is scalable, interpretable, and feasible for implementation across academic and community settings, providing a robust tool for patient stratification, treatment planning, and trial design.
Teaching AI for Radiology Applications: A Multisociety‑Recommended Syllabus from the AAPM, ACR, RSNA, and SIIM
Kitamura, Felipe , Kline, Timothy L. , Warren, Daniel , Santos, Igor , Bialecki, Brian , O'Donnell, Kevin , Morgan, Matthew B. , Safdar, Nabile , Andriole, Katherine P. , Geis, J. Raymond , Dreyer, Keith J. , Wood, Monica J. , Langer, Steve G., Farina, Eduardo Moreno Júdice de Mattos , Reiser, Ingrid , Wald, Christoph , Cook, Tessa S. , Tenenholtz, Neil , Kline, Timothy, Langer, Steve, Kitamura, Felipe C , Reiser, Ingrid , Moy, Linda , Daneshjou, Roxana , Maleki, Farhad , Gichoya, Judy Wawira , Wiggins, Walter F. , Flanders, Adam E , Allen, Bibb , Lungren, Matt , Kohli, Marc , Shih, George , Kahn, Charles E. , Giger, Maryellen , Mongan, John

Mayo Clinic

Medical Physics | October 1, 2025 | Volume: 52 | Issue: 10 | Pages: No page available

10.1002/mp.17779 | PMID 41030223 Get It

Abstract Medical imaging is undergoing a transformation driven by the advent of new, highly effective, machine learning techniques paired with increases in computational capabilities (Cheng et al. 2021; Gilson et al. 2023; Almeida et al. 2024; Krishna et al. 2024). These advanced algorithms have the potential to improve disease detection, diagnosis, prognosis, and treatment outcomes. However, the complexity of machine learning models, the large amounts of curated and annotated data required by some methods, and the potential for bias and error make it challenging for individuals to safely and effectively leverage these methods (Lin et al. 2024; Guo et al. 2024; Xu et al. 2024; Linguraru et al. 2024; Wood et al. 2019). To address these challenges, the American Association of Physicists in Medicine (AAPM), American College of Radiology (ACR), Radiological Society of North America (RSNA), and Society for Imaging Informatics in Medicine (SIIM) have worked together to develop a syllabus detailing a recommended set of competencies for medical imaging professionals interacting with these systems. This guide is aimed at four different personas: users of AI systems, purchasers of AI systems, individuals who provide clinical expertise during the development of AI systems (“clinical collaborators”), and developers of AI systems.1 This is a syllabus, not a curriculum, and is intentional in this scope. Recognizing that individuals may benefit from different presentations of the same material, this work enumerates a series of relevant competencies but does not prescribe, nor offer, a method of instruction (Schuur, Rezazade Mehrizi, and Ranschaert 2021; Garin et al. 2023). By addressing the task‐specific demands of each role, this guide will enable medical imaging professionals to utilize machine learning systems more safely and effectively, ultimately improving patient care and outcomes.
Quality assessment of artificial intelligence‐generated versus human‐written hospital summaries evaluating detail, usefulness, and continuity of care
Ryu, Alexander J. , Heaton, Heather A. , Challener, Douglas , Ayanian, Shant , Ryu, Alexander, O'horo, John, Heaton, Heather, Challener, Douglas W. , Ryu, Alexander J. , O’Horo, John C.

Mayo Clinic

Journal of Hospital Medicine | October 1, 2025 | Volume: 21 | Issue: 4 | Pages: 375-379

10.1002/jhm.70163 | PMID 41028943 Get It

Abstract Background Hospital discharge summaries are critical for ensuring continuity of care, but their quality often varies. Large language models (LLMs) have the potential to standardize and enhance the efficiency of this documentation process. Objectives To evaluate the quality of hospital discharge summaries created by an LLM‐based hospital course drafting tool created by Epic Systems compared with human‐written summaries. Methods Retrospective study at a single tertiary‐care institution in 2024. The cohort included 100 adult hospitalizations lasting >72 h across medical and surgical dismissing services. No interventions were performed. Summaries (LLM‐generated vs. human‐written) were independently reviewed using a standardized rubric covering nine domains (e.g., comprehensiveness, clarity, relevance). Scores were normalized and compared. Readability was assessed using Flesch Reading Ease. Results LLM‐generated summaries outperformed human‐written summaries across all criteria ( p < .05), with the greatest difference observed in comprehensiveness (LLM median 0.62 vs. human −0.23). Human‐written summaries from surgical services scored lower than those from medical services, but LLM performance was consistent across both. Human summaries had higher Flesch Reading Ease scores (33.11 vs. 26.2; p < .05), reflecting simpler language. Conclusions LLM‐generated summaries demonstrated superior quality, consistency, and clinical utility compared with human‐written summaries, highlighting their potential to improve documentation efficiency and standardization.
International, Multispecialty Expert Consensus on Nomenclature for Facial Paralysis
Oyer, Samuel L. , Baptista, Rachel, Boahene, Kofi , Byrne, Patrick J., Chuang, David Chwei‐Chin , Dey, Jacob K. , Diels, Jackie , Hadlock, Tessa A. , Hetzler, Laura , Klebuc, Michael, Labbé, D., Loyo, Myriam , Miller, Matthew Q. , Pepper, Jon‐Paul , Rozen, Shai M. , Snyder‐Warwick, Alison K. , Stephan, Scott J., Tzafetta, Kallirroi , Azizzadeh, Babak , Byrne, Patrick , Dey, Jacob K , Lassaletta, Luis , Loyo, Myriam , Miller, Matthew Q , Pepper, Jon-Paul , Rozen, Shai , Azizzadeh, Babak , Borschel, Gregory Howard , Guerreschi, Pierre , Gur, Eyal , Kim, Jennifer , Mardini, Samir

Mayo Clinic

Facial Plastic Surgery & Aesthetic Medicine | September 30, 2025 | Volume: 27 | Issue: 5 | Pages: 408-415

10.1177/26893614251363957 | PMID 40876002 Get It

Background: Variable terminology is used in the literature to describe facial synkinesis and hypertonicity following incomplete recovery from facial paralysis and its associated medical and surgical treatments. Study Objectives: Establish a nomenclature consensus for this condition among a group of facial nerve experts. Design Type: Consensus study. Methods: Using modified Delphi methodology, an international, multidisciplinary group of facial nerve experts reviewed the terminology for the name of the clinical condition and treatments of interest. Online surveys and a virtual discussion were performed to establish consensus, defined a priori as agreement by 80% of the group. Results: Twenty-five facial nerve experts established consensus after three Delphi rounds. Consensus terminology for the condition is “facial synkinesis” with 84% agreement. Medical treatment is termed “chemodenervation” with 100% agreement. Surgical treatments including “selective facial neurectomy,” “selective facial neurotomy,” “selective facial myectomy,” and “selective facial myotomy,” were defined and reached agreement of 100%. Conclusions: This international group of facial nerve experts has recommended standardized nomenclature for the condition of facial synkinesis and its various treatments. While “facial synkinesis” reached consensus as the preferred term, some experts noted it may insufficiently describe the full clinical spectrum, which includes muscle hypertonicity, weakness, and spontaneous twitching.
“No Pain, More Gain”: Subjective Responses to a T’ai Chi and Qigong Program For Back Pain
Caldwell, Karen , Schlagal, Robert, DeCelle, Sharon , Simmons, Seymour , Yang, Lin, Abduljawad, Sahar, Ayar, Jay, Singh, Jaspal , Sheeler, Robert D. , Flynn, Patricia R., Knapp, Kenneth , Härtl, Roger , Caldwell, Karen , Abduljawad, Sahar , Ayar, Jay , Sheeler, Robert, Yang, Yang , Yang, Lin

Mayo Clinic

Global Advances in Integrative Medicine and Health | September 30, 2025 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/27536130251384679 | PMID 41041080 Get It

Background Low back pain is the leading cause of disability worldwide. Multidisciplinary approaches to chronic pain can support resilience in recovery of functioning. The ancient arts of t’ai chi and qigong have been touted for centuries as multimodal approaches to health and healing. An RCT of an on-line t’ai chi and qigong program for individuals with chronic low back pain found clinically significant improvements in pain, physical function, and quality of life. The program consisted of the integrated practice of t’ai chi movement and the stillness of qigong practice. Meditations in the program focused on developing positive mental attitudes to support resilience in managing the emotional challenges of pain and disease. Objective The purpose of the current qualitative study aimed to better understand participants’ experiences during the online Heal and Strengthen the Spine with T’ai Chi and Qigong (HSSTQ) program. Methods Written feedback was received from 96 program participants, and semi-structured interviews were completed with 20 participants. Interviews were transcribed and coded based upon the written feedback and interview questions. A thematic narrative was developed from the coded segments of texts and reviewed by participants in a member check. Results Three interlocking themes characterized the experiences of participants in the program: (1) participants learned skills to relieve back pain including moderation in movement; (2) the holistic nature of the program enabled a range of benefits for participants beyond pain reduction; and (3) personal healing experience, the enthusiasm of the instructor, the program itself, and available staff resources motivated individuals to participate. Conclusion The conclusion from this study and the initial RCT is that a virtually delivered integrated tai chi, qigong, and meditation program may be a viable treatment option for adults with low back pain.
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2
Harding, James J. , Oh, Do‐Youn , Macarulla, Teresa , Goyal, Lipika , Varkaris, Andreas , Palmieri, Lola‐Jade , Ikeda, Masafumi , Kondo, Shunsuke , Bai, Li‐Yuan , Ueno, Makoto , Papadopoulos, Kyriakos P. , Shroff, Rachna T. , Kizilbash, Sani H. , Liao, Chih‐Yi , Azad, Nilofer S. , Jaeckle, Kurt A. , Bender, Mark H. , Varughese, Sunoj Chacko , Sachdeva, Deepa , Radtke, David B. , Gueorguieva, Ivelina , Chen, Hsiao-Rong , Liu, Hui , Xu, Xiangyuan , Macarulla, Teresa , Chen, Li-Tzong , Papadopoulos, Kyriakos P , Shroff, Rachna T , Kizilbash, Sani H , Hollebecque, Antoine , Adeva, Jorge , Cosman, Rasha , Yokota, Tomoya , Park, Joon Oh , Turk, Anita , Liao, Chih-Yi , Satoh, Taroh , Borad, Mitesh J , El-Khouiery, Anthony B , Azad, Nilofer , Jaeckle, Kurt A , Loong, Herbert H , Yong, Wei-Peng , Bender, Mark H , Varughese, Sunoj Chacko , Sachdeva, Deepa , Radtke, David B , Gueorguieva, Ivelina , Szpurka, Anna M , Chen, Hsiao-Rong , Liu, Hui , Xu, Xiaojian , Rodon, Jordi , Ikeda, Masafumi , Goyal, Lipika , Harding, James J , Chen, Li‐Tzong , Adeva, Jorge , Yokota, Tomoya , Borad, Mitesh J. , El-Khoueiry, Anthony B. , Loong, Herbert H. , Yong, Wei Peng

Mayo Clinic

Clinical Cancer Research | September 30, 2025 | Volume: 31 | Issue: 23 | Pages: 4920-4932

10.1158/1078-0432.ccr-25-0174 | PMID 41026608 Get It

Abstract Purpose: Isocitrate dehydrogenase (IDH) 1/2–isoform inhibitors have clinical efficacy in IDH1/IDH2-mutated neoplasms. However, primary resistance and secondary resistance limit their therapeutic potential. LY3410738, an oral, brain-penetrant, dual IDH1/IDH2-mutated isoform-selective inhibitor, was designed to overcome resistance. Patients and Methods: This global, multicenter, open-label, phase I study of patients with IDH-mutant solid tumors evaluated LY3410738 as monotherapy (dose escalation) for advanced solid tumors in combination with cisplatin–gemcitabine (CISGEM) for newly diagnosed cholangiocarcinoma or with durvalumab for relapsed/refractory cholangiocarcinoma (dose expansion; NCT04521686). Primary objectives were the maximum tolerated dose, recommended phase II dose, and preliminary antitumor activity. Safety, pharmacokinetics, inhibition of D-2-hydroxyglutarate, and ctDNA were assessed. Results: Overall, 119 patients received LY3410738 alone (N = 94) or in combination with CISGEM (N = 19) or durvalumab (N = 6). No dose-limiting toxicities were observed; the maximum tolerated dose was not determined. Common adverse events included nausea, vomiting, and decreased appetite. Overall response rates of 5.2% and 11.1% and disease control rates of 56.9% and 63.0% were observed for patients with relapsed/refractory IDH1- or IDH2-mutant cholangiocarcinoma or IDH1-mutant glioma, respectively. D-2-hydroxyglutarate normalization was rapid and durable. In dose-expansion cohorts, combination treatments were tolerable, with one dose-limiting toxicity in the durvalumab cohort. LY3410738 plus CISGEM demonstrated a response rate of 42.1%, a median duration of response of 8.1 months, and a median progression-free survival of 10.2 months for patients with newly diagnosed IDH-mutant cholangiocarcinoma. Conclusions: LY3410738 demonstrated largely cytostatic antitumor activity in IDH1- or IDH2-mutated cholangiocarcinoma and IDH1-mutated gliomas. LY3410738 plus CISGEM exhibited favorable antitumor activity in patients with treatment-naïve IDH-mutated cholangiocarcinoma, warranting further exploration as a treatment strategy.